Trial Profile
Phase II, single-arm study of AZD6094 (Volitinib) in combination with docetaxel, in advanced gastric adenocarcinoma patients with MET amplification as a second-line chemotherapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Savolitinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2022 Status changed from recruiting to completed.
- 26 Dec 2019 Planned End Date changed from 1 Jan 2019 to 1 Dec 2020.
- 26 Dec 2019 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2020.